Fulminant Idiopathic Intracranial Hypertension
Neurol 68:229-232, Thambisetty,M.,et al, 2007
Recent Advances in the Diagnosis and Management of Cluster Headache
BMJ 376:e059577, Schindler, E. & Burish, M.J., 2022
Diagnosis and Management of the Antiphospholipid Syndrome
NEJM 378:2010-2021, Garcia, D. & Erkan, D., 2018
Acute Viral Encephalitis
NEJM 379:357-366, Tyler,K.L., 2018
Patent Foramen Ovale Closure, Antiplatelet Therapy or Anticoagulation Therapy Alone for Management of Cryptogenic Stroke?
BMJ 362:k2515, Kuijpers, T.,et al, 2018
Increasing Prevalence of Vascular Risk Factors in Patients with Stroke
Neurol 89:1985-1994, Otite, F.O.,et al, 2017
Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation: Current Status, Special Situations, and Unmet Needs
Lancet 386:303-310, Verheugt, F.W.A. & Granger, C.B., 2015
Serotonin Syndrome
BMJ 348:g1626, Buckley, N.A.,et al, 2014
Drug Treatment of Epilepsy in Adults
BMJ 348:g2546, Schmidt, D. & Schachter, S.C., 2014
Viral Infections of the Nervous System, Chronic Meningitis, and Prior Diseases, Acute Anterior Poliomyelitis
Adams & Victors Principles of Neurology, Chp 33, pg 763, Ropper, A.H.,et al, 2014
Clinicopathologic Conference, Rabies Encephalitis
NEJM 368:172-180, Case 1-2013, 2013
Closure of Patent Foramen Ovale versus Medical Therapy after Cryptogenic Stroke
NEJM 368:1092-1100,1152, Carroll, J.D.,et al, 2013
Percutaneous Closure of Patent Foramen Ovale in Cryptogenic Embolism
NEJM 368:1083-1091,1152, Meier, B.,et al, 2013
Patent Foramen Ovale Closure and Medical Treatments for Secondary Stroke Prevention
Stroke 43:422-431, Kitsios,G.D.,et al, 2012
Closure or Medical Therapy for Cryptogenic Stroke with Patent Foramen Ovale
NEJM 366:991-999,1048, Furlan,A.J.,et al, 2012
Cluster Headache
BMJ 344:e2407, Nesbitt,A.D.,et al, 2012
Guidelines for the Prevention of Stroke in Patients With Stroke or Transient Ischemic Attack: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association
Stroke 42:227-276, Furie,K.L.,et al, 2011
Study Design of the CLOSURE I Trial: A Prospective, Multicenter, Randomized, Controlled Trial to Evaluate the Safety and Efficacy of the STARFlex Septal Closure System Versus Best Medical Therapy in Patients With Stroke or TIA Due to Presumed Paradoxical Embolism Through a PFO
Stroke 41:2872-2883, Furlan,A.J.,et al, 2010
Recurrent Cerebral Ischemia in Medically Treated Patent Foramen Ovale: A Meta-Analysis
Neurol 73:89-97,84, Almekhlafi,M.A.,et al, 2009
Induced Hypothermia and Fever Control for Prevention and Treatment of Neurological Injuries
Lancet 371:1955-1969, Polderman,K.H., 2008
Management of Stroke in Infants and Children: A Scientific Statement From a Special Writing Group of the American Heart Association Stroke Council and the Council on Cardiovascular Disease in the Young
Stroke 39:2644-2691, Roach,E.S.,et al., 2008
Secondary Stroke Prevention With Ximelagatran Versus Warfarin in Patients With Atrial Fibrillation: Pooled Analysis of SPORTIF III and V Clinical Trials
Stroke 38:874-880, Akins,P.T.,et al, 2007
Guidelines for Prevention of Stroke in Patients With Ischemic Stroke or Transient Ischemic Attack
Stroke 37:577-617, Sacco,R.L.,et al, 2006
Therapeutic Strategies After Examination by Transesophageal Echocardiography in 503 Patients with Ischemic Stroke
Stroke 37:859-864, Harloff,A.,et al, 2006
Prevalence of Ulnar Neuropathy in Patients Receiving Hemodyalysis
Arch Neurol 62:271-275, Nardin, R., et al, 2005
Ximelagatran vs Warfarin for Stroke Prevention in Patients with Nonvalvular Atrial Fibrillation
JAMA 293:690-698,736, SPORTIF Executive Steering Committee for the SPORTIF V Investigators, 2005
10 Most Commonly Asked Questions About Which Antiplatelet Agent to Prescribe
The Neurologist 9:318-322, Adams,H.P. Jr., 2003
Recurrent Cerebrovascular Events Associated With Patent Foramen Ovale, Atrial Septal Aneurysm, or Both
NEJM 345:1740-1746, Mas,J.,et al, 2001
Stroke Prevention
Neurol Clin 18:321-341, Wein,T.H. &Bornstein,N.M., 2000
Reye's Syndrome in the United States from 1981 Through 1997
NEJM 340:1377-1382,1423, Belay,E.D.,et al, 1999
Near-Fatal Heat Stroke During the 1995 Heat Wave in Chicago
Ann Int Med 129:173-181, Damatte,J.E.,et al, 1998
Clinicopath Conf
Rabies, Involving the Central and Peripheral Nervous Systems and Heart, Case 21-1998, NEJM 339:105-1, 2, 1, 1998
Preventing Stroke Recurrence in Patients with Patent Foramen Ovale: Antithrombotic Therapy, Foramen Closure, or Therapeutic Abstention? A Decision Analytic Perspective
Am Heart J 135:532-541, Nendaz,M.R.,et al, 1998
Surgical Closure of Patent Foramen Ovale in Cryptogenic Stroke Patients
Stroke 28:2376-2381, Homma,S.,et al, 1997
Prognosis After Stroke Followed by Surgical Closure of Patent Foramen Ovale
Neurol 47:1162-1166, Devuyst,G.,et al, 1996
Treatment of End Stage Dilated Cardiomyopathy
Br Heart J 72:S52-S56, O'Connell,J.B.,et al, 1996
A Comparison of Surgical & Medical Therapy for Atrial Septal Defect in Adults
NEJM 333:469-473, 5131995., Konstantinides,S.,et al, 1995
The Effect of Intensive Diabetes Therapy on Development & Progression of Neuropathy
The Diabetes Control & Compl Trial Res Gr, Ann Int Med 122:561-56895., , 1995
Preoperative MRI Predicts Outcome of Temporal Lobectomy:An Actuarial Analysis
Neurol 45:1358-1363, 12481995., Berkovic,S.F.,et al, 1995
Neurocysticercosis in Houston, Texas:A Report of 112 Cases
Medicine 73:37-52, Shandera,W.X.,et al, 1994
Patent Foramen Ovale and Brain Infarct:Echocardiographic Predictors, Recurrence, and Prevention
Stroke 25:782-786, Hanna,J.P.,et al, 1994
Epilepsy
JNNP 57:264-277, Chadwick,D., 1994
Growth Factors:Potential Therapeutic Applications in Neurology
JNNP 54:1445-1450, Drago,J.,et al, 1994
Antimicrobial Prophylaxis in Neurosurgery and After Head Injury
Lancet 344:1547-1551, deLouvois,J.,et al, 1994